Kano Therapeutics
Mark Bathe is a Professor at MIT, with a focus on engineering nucleic acids for targeted delivery of therapeutics and vaccines, phenotypic profiling of neuronal circuits, and molecular computing. Mark is also a SIY Certified Teacher at Search Inside Yourself Leadership Institute, Director of MIT's New Engineering Education Transformation program, and a Co-Founder at Cache DNA and Kano Therapeutics. In addition, Mark is a member of the HMS Initiative for RNA Medicine at Harvard Medical School and an Associate Member at the Broad Institute of MIT & Harvard. With a background in Mechanical Engineering from MIT, Mark has a strong foundation in various interdisciplinary fields.
This person is not in the org chart
This person is not in any teams
Kano Therapeutics
Kano Therapeutics is a founder-led biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them, empowering scientists, labs, and companies with the building blocks they need to cross the chasm to cures.